The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Distinct cytoplasmic staining in breast and colorectal carcinomas. Several other adenocarcinomas were also distinctly stained. Nevertheless prostate and liver cancers, malignant melanomas and gliomas were mostly negative.
Malignant tissues showed cytoplasmic staining in variable intensity. Strongest staining in liver, thyroid, and breast cancers. Squamous cell carcinomas, renal cancers, malignant gliomas and lymphomas were mainly negative.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
